Major TAVR policy changes appear to be on the way—should clinicians be excited or concerned? Leading U.S. medical societies are sharing their early reactions.
The Shockwave C2 Aero Coronary IVL Catheter is based on years of user feedback. For example, it was built with improved deliverability and repositioning capabilities in mind.
Up to 30% of U.S. patients carry genetic variations that reduce the effectiveness of clopidogrel, an antiplatelet medication sold under the brand name Plavix.
When CMS finalized coverage for cardiac ablations performed in ASCs, experts from HRS and ACC published recommendations for performing those procedures safely and effectively. One of the cardiologists behind that guidance shared some important takeaways with Cardiovascular Business.
Experts agree that most patients younger than 65 should be treated with surgery instead of TAVR. According to a new real-world analysis, however, more and more of these patients are undergoing TAVR.
Follow-up care after a successful heart transplant can be challenging—both for providers and their patients. Consider, for example, the fact that so many patients who develop complications never actually present with symptoms.
